<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00270504</url>
  </required_header>
  <id_info>
    <org_study_id>1-044TWUS</org_study_id>
    <nct_id>NCT00270504</nct_id>
  </id_info>
  <brief_title>Memokath® 044TW Stent for Treatment of Urethral Stricture</brief_title>
  <official_title>Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pnn Medical DK</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pnn Medical DK</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the placement of a temporary urethral stent for&#xD;
      up to 12 months, following dilation or internal urethrotomy (cutting open), results in a&#xD;
      higher rate of urethral patency during the first year of follow-up when compared to the&#xD;
      control group that does not receive a stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with bulbar urethral stricture are 2:1 randomised for either urethral dilation or&#xD;
      internal urethrotomy with (treatment group) or without (control group) subsequent stenting.&#xD;
      All patients are followed for up to one year at 4-6 weeks, 3, 6, 9 and 12 months with visual&#xD;
      assessment (urethroscopy) of urethral patency at the treated segment of the urethra. The&#xD;
      stent is removed at one year. In case of premature stent removal the patient is also followed&#xD;
      for up to one year unless further intervention is decided.&#xD;
&#xD;
      Control patients are offered the stent treatment option if the stricture recurs within the&#xD;
      observation period but this group is separately analysed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent/control effectiveness - urethral patency</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak urinary flow rate</measure>
    <time_frame>Immediate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention</measure>
    <time_frame>Short term</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard survey instruments (QOL, IPSS etc.)</measure>
    <time_frame>15 mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent placement success</measure>
    <time_frame>immediate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent removal success</measure>
    <time_frame>immediate</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">92</enrollment>
  <condition>Urethral Stricture</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Memokath stenting</intervention_name>
    <description>Urethral Stenting</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males &gt; 21 years of age&#xD;
&#xD;
          2. Recurrent stricture of the bulbar urethra:&#xD;
&#xD;
               1. &lt; 50 mm in length on urethrography; and which&#xD;
&#xD;
               2. has a segment unable to accommodate a 16Fr flexible cystoscope&#xD;
&#xD;
          3. Healthy tissue on both sides of stent&#xD;
&#xD;
          4. Urinary flow in the abnormal range of the Siroky nomogram.&#xD;
&#xD;
          5. Written informed consent obtained prior to participation in the study&#xD;
&#xD;
          6. Patients must be available for all follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Strictures:&#xD;
&#xD;
               1. outside the bulbous urethra&#xD;
&#xD;
               2. associated with, or suspected to be, urethral carcinoma&#xD;
&#xD;
               3. secondary to pelvic distraction injuries&#xD;
&#xD;
          2. Inability to enlarge the bulbar urethral stricture to &gt; 26 Fr.&#xD;
&#xD;
          3. Presence of any other urologic implant&#xD;
&#xD;
          4. Presence of urethral diverticuli&#xD;
&#xD;
          5. History of hypospadias repair&#xD;
&#xD;
          6. Presence or prior history of balanitis xerotica obliterans.&#xD;
&#xD;
          7. Uncontrolled bleeding disorder&#xD;
&#xD;
          8. Active urinary tract infection&#xD;
&#xD;
          9. Any urological condition that would be likely to require additional urethral&#xD;
             instrumentation during the period of the investigation, including, but not limited to,&#xD;
             benign prostatic hypertrophy requiring treatment; use of alpha blockers; active&#xD;
             prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder&#xD;
             malignancy; or any recurrent urinary stone formation.&#xD;
&#xD;
         10. Serum creatinine &gt; 2.0 mg/dl or evidence of progressive renal disease&#xD;
&#xD;
         11. Concurrent participation in another clinical investigation&#xD;
&#xD;
         12. Current illness that might confound the results of this investigation&#xD;
&#xD;
         13. Inability to participate in all of the necessary study activities&#xD;
&#xD;
         14. Inability or unwillingness to return for all required follow-up visits&#xD;
&#xD;
         15. Inability or unwillingness to sign the patient informed consent document&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerry Jordan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sentara/Engineers and Doctors</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jack McAninch</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mississippi Urology</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Urology</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urological Associates</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devine-Tidewater Urology</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 23, 2005</study_first_submitted>
  <study_first_submitted_qc>December 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2005</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director of Clinical and Regulatory</name_title>
    <organization>Pnn Medical</organization>
  </responsible_party>
  <keyword>Memokath</keyword>
  <keyword>Urethral stricture</keyword>
  <keyword>urethral stent</keyword>
  <keyword>Bulbar urethral stricture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urethral Stricture</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

